10 / 25
•
Multicentric and retrospective
•
mCRC patients with plasma samples at diagnosis,
before second and/or third line of treament
•
Demographics,
pathology
and
treatment
outcome were analized.
•
BEAMing in Plasma (sens. 0.02-0.04%)
•
To correlate
RAS
mt MAF with disease
burden (number of metastasis site and
CEA), primary location and treatment
line.
•
To analyze impact of
RAS
mt MAF in
Overall Survival (OS) and Progression
Free Survival (PFS) at different stages of
disease.
Exon 4
Exon 3
Exon 2
Exon 4
Exon 3
Exon 2
12 13
12 13
59 61
117 146
KRAS
NRAS
59 61
117 146
DESIGN
OBJECTIVES
Design & Objectives